Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Guselkumab for Scalp Psoriasis
Recruiting3 awardsPhase 4
San Francisco, California
This trial studies how Guselkumab, a medication for psoriasis, affects immune cells in patients with moderate to severe scalp psoriasis. Guselkumab works by blocking a protein to reduce inflammation and symptoms.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.